Seven and Eight

Seven and Eight Biopharma is a biopharmaceutical company dedicated to the discovery and development of novel targeted cancer immunotherapies and is a leader in dendritic cell reprogramming therapies, partnering with TLR7/8 agonists to activate innate immunity and generate adaptive immune responses.The primary goal of Seven and Eight Biopharma is to develop a series of proprietary novel immuno-oncology (IO) drugs that synergize with PD-1/PD-L1 and feature substantial differentiation strategies. We have established a three-tier strategy based on our proprietary TLR7/8 technology, which includes first-in-class systemic delivery, optimal localized delivery, and targeted delivery via antibody-drug conjugates.